AnGes

4563.TTSE GROWTHPharmaceutical

Key numbers · FY ended 2025-12

Operating income−¥5.1bn—Net income (owners)−¥5.1bn—Total assets¥5.4bn+15.8% YoY EPS (basic)¥-14.44+87.9% YoY

Full financial history and reports →

Stock price4563 · View chart ↗

Open the price chart on TradingView.

Latest filings

Tue, Oct 27 · JST1 filing

11:525% STAKEAnGes · Growth Partners Co., Ltd. + 1 joint holder · 30.78% → 29.74%−1.04pp

Thu, Sep 24 · JST1 filing

11:405% STAKEAnGes · Cantor Fitzgerald Europe · 18.14% → 0.00%−18.14pp

Fri, Sep 4 · JST1 filing

16:515% STAKEAnGes · Growth Partners Co., Ltd. + 1 joint holder · 31.45%new 31.45%

Fri, Jan 9 · JST1 filing

13:585% STAKEAnGes · Cantor Fitzgerald Europe · 19.99% → 18.14%−1.85pp

Mon, Dec 1 · JST1 filing

14:375% STAKEAnGes · Cantor Fitzgerald Europe · 19.99%new 19.99%

All filings →

Major holders (5%+) · 2

Holder	Stake	Change	Filed
Growth Partners Co., Ltd.	29.74%	-1.04pp	2026-10-27
Noriatsu Furukawa	15.39%	—	2026-09-04

Each holder's own ratio from its most recent large-shareholding report.